valbenazine
Ingrezza, a Neurocrine Biosciences Drug, Receives FDA Approval for Tardive Dyskinesia Treatment
Neurocrine Biosciences, Ingrezza, FDA approval, tardive dyskinesia, neuropsychiatric disorder, valbenazine, first-of-its-kind treatment.
Actionable Insights Powered by AI
Neurocrine Biosciences, Ingrezza, FDA approval, tardive dyskinesia, neuropsychiatric disorder, valbenazine, first-of-its-kind treatment.